RS54743B1 - Agonisti adenozina a1 za tretman glaukoma i očnog pritiska - Google Patents
Agonisti adenozina a1 za tretman glaukoma i očnog pritiskaInfo
- Publication number
- RS54743B1 RS54743B1 RS20160304A RSP20160304A RS54743B1 RS 54743 B1 RS54743 B1 RS 54743B1 RS 20160304 A RS20160304 A RS 20160304A RS P20160304 A RSP20160304 A RS P20160304A RS 54743 B1 RS54743 B1 RS 54743B1
- Authority
- RS
- Serbia
- Prior art keywords
- hydrogen
- methyl
- group
- pyrrolidine
- piperidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Jedinjenje, naznačeno time, što je predstavljeno formulom (I)u kojojA je kiseonik ili sumpor,R1 je vodonik ili grupa sa formulomu kojima# je veza prema atomu kiseonika,L1 je linearni (C2-C4)-alkandiil,L2 je linearni (C1-C3)-alkandiil,R3 i R8 su identični ili različiti i nezavisno izabrani iz grupe koja obuhvata vodonik, metil, propan-2-il, propan-1-il, 2-metilpropan-1-il, 1-metilpropan-1-il, butan-1-il, tert-butil, fenil, benzil, p-hidroksibenzil, indol-3-ilmetil, imidazol-4-ilmetil, hidroksimetil, 2-hidroksietil, 1-hidroksietil, merkaptometil, metiltiometil, 2-merkaptoetil. 2-metiltioetil, karbamoilmetil, 2-karbamoiletil, karboksimetil, 2-karboksietil, 4-aminobutan-1-il, 4-amino-3-hidroksibutan-1-il, 3-aminopropan-1-il, 2-aminometil, aminometil, 3-gvanidinopropan-1-il, 3-ureidopropan-1-il,R6 i R9 su nezavisno izabrani iz vodonika ili metila,R7 je vodonik ili (C1-C4)-alkil, iliR7 i R3 formiraju, zajedno sa atomima na kojima su spojeni, pirolidin- ili piperidin-prsten,R10 i R11 su identični ili različiti i su nezavisno izabrani iz vodonika ili (C1-C4)-alkila, pri čemu (C1-C4)-alkil može da bude supstituisan sa jednom grupom koja je izabrana iz hidroksi, (C1-C4)-alkoksi, amino, mono-(C1-C4)-alkilamino ili di-(C1-C4)-alkilamino, iliR10 i R8 formiraju, zajedno sa atomima na kojima su spojeni, pirolidin- ili piperidin-prsten, aR12 je vodonik ili hidroksikarbonil,R2 je vodonik ili grupa sa formulom -CH2OR1, pri čemu je R1 definisan kao malopre,R3 je vodonik, metil ili etil,R4 je vodonik, metil ili etil,iliR3 i R4 formiraju, zajedno sa atomom azota na kojeg su spojeni, azetidin-, pirolidin- ili piperidin-prsten, pri čemu pomenuti azetidin-, pirolidin- ili piperidin-prsten može da bude supstituisan sa jednim ili 2 supstituenta nezavisno izabrana iz grupe koja obuhvata fluoro, trifluorometil, metil, etil, metoksi i etoksi, ili njegove soli, solvati i solvati pomenutih soli za upotrebu u postupku za tretman i/ili profilaksu glaukoma, normotenzivnog glaukoma, očnog pritiska i/ili njihovih kombinacija.Prijava sadrži još 11 patentnih zahteva.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10175151 | 2010-09-02 | ||
| PCT/EP2011/064829 WO2012028585A1 (en) | 2010-09-02 | 2011-08-29 | Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension |
| EP11752517.0A EP2611415B1 (en) | 2010-09-02 | 2011-08-29 | Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS54743B1 true RS54743B1 (sr) | 2016-10-31 |
Family
ID=44582992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160304A RS54743B1 (sr) | 2010-09-02 | 2011-08-29 | Agonisti adenozina a1 za tretman glaukoma i očnog pritiska |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20120058983A1 (sr) |
| EP (1) | EP2611415B1 (sr) |
| JP (1) | JP5875585B2 (sr) |
| KR (1) | KR20140091457A (sr) |
| CN (1) | CN103249400B (sr) |
| AP (1) | AP3413A (sr) |
| AU (1) | AU2011298430B2 (sr) |
| BR (1) | BR112013005224A2 (sr) |
| CA (1) | CA2809700A1 (sr) |
| CL (2) | CL2013000599A1 (sr) |
| CR (1) | CR20130094A (sr) |
| CY (1) | CY1117458T1 (sr) |
| DK (1) | DK2611415T3 (sr) |
| EA (1) | EA028411B1 (sr) |
| ES (1) | ES2570659T3 (sr) |
| HK (1) | HK1188138A1 (sr) |
| HR (1) | HRP20160532T1 (sr) |
| HU (1) | HUE027295T2 (sr) |
| MA (1) | MA34489B1 (sr) |
| MX (1) | MX2013002396A (sr) |
| MY (1) | MY160383A (sr) |
| NZ (1) | NZ607624A (sr) |
| PL (1) | PL2611415T3 (sr) |
| RS (1) | RS54743B1 (sr) |
| SG (1) | SG187974A1 (sr) |
| SI (1) | SI2611415T1 (sr) |
| TW (1) | TWI516266B (sr) |
| UA (1) | UA111947C2 (sr) |
| WO (1) | WO2012028585A1 (sr) |
| ZA (1) | ZA201302340B (sr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013211957B2 (en) | 2012-01-26 | 2017-08-10 | Inotek Pharmaceuticals Corporation | Anhydrous polymorphs of (2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof |
| US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| KR20160094974A (ko) * | 2013-12-12 | 2016-08-10 | 바이엘 파마 악티엔게젤샤프트 | 신장 질환에 대한 의약으로서의 아데노신 a1 작용제 |
| EP3093021B1 (en) * | 2014-01-10 | 2021-06-02 | Santen Pharmaceutical Co., Ltd. | Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition |
| LT3292133T (lt) * | 2015-05-06 | 2019-08-26 | Bayer Pharma Aktiengesellschaft | 2-{4-[2-({[2-(4-chlorfenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-dician-6-(pirolidin-1-il)piridin-4-il]fenoksi}etil-l-alanil-l-alaninato monohidrochlorido gamybos būdas |
| WO2017137528A1 (en) | 2016-02-12 | 2017-08-17 | Charité - Universitätsmedizin Berlin | Adenosine a1 receptor agonist for use in treatment of status epilepticus |
| CN112545983A (zh) * | 2020-12-18 | 2021-03-26 | 合肥中龙神力动物药业有限公司 | 一种复方硫酸新霉素滴眼液及其制备方法和应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4052510A (en) | 1974-12-18 | 1977-10-04 | Sandoz, Inc. | 4-alkyl-2,6-di(secondary or tertiary alkylamino) pyridines, compositions thereof and methods for treating diabetes and obesity |
| TW299333B (sr) | 1992-12-29 | 1997-03-01 | Takeda Pharm Industry Co Ltd | |
| DE4334919A1 (de) * | 1993-10-13 | 1995-04-20 | Liedtke Pharmed Gmbh | Grenzwertig wirksame Arzneiformen mit Betablockern |
| EP0765327B1 (en) | 1994-06-16 | 1999-07-21 | Pfizer Inc. | Pyrazolo and pyrrolopyridines |
| DE4430638A1 (de) | 1994-08-29 | 1996-03-07 | Bayer Ag | Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel |
| JPH09132529A (ja) | 1995-11-09 | 1997-05-20 | Ono Pharmaceut Co Ltd | 一酸化窒素合成酵素阻害剤 |
| EP0876379A1 (en) | 1996-01-17 | 1998-11-11 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| AU709190B2 (en) | 1996-01-29 | 1999-08-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists |
| JPH10324687A (ja) | 1997-02-19 | 1998-12-08 | Nippon Soda Co Ltd | ピロール化合物、製法および農園芸用殺菌剤 |
| WO1998054139A1 (de) | 1997-05-30 | 1998-12-03 | Basf Aktiengesellschaft | Verfahren zur herstellung substituierter thiopyridine |
| RU2215004C2 (ru) | 1997-07-16 | 2003-10-27 | Ново Нордиск А/С | Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата |
| US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19947154A1 (de) | 1999-10-01 | 2001-10-04 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| IL150912A0 (en) | 2000-02-25 | 2003-02-12 | Hoffmann La Roche | Adenosine receptor modulators |
| PL359416A1 (en) | 2000-07-18 | 2004-08-23 | Yamanouchi Pharmaceutical Co, Ltd. | Medicine comprising dicyanopyridine derivative |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| AU2002227243A1 (en) | 2000-12-11 | 2002-06-24 | E.I. Du Pont De Nemours And Company | Quinazolinones and pyridinopyrimidinones for controlling invertebrate pests |
| AU3113902A (en) | 2000-12-21 | 2002-07-01 | Bristol Myers Squibb Co | Thiazolyl inhibitors of tec family tyrosine kinases |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110747A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10134481A1 (de) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
| DE10238113A1 (de) * | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
| JP2003183254A (ja) | 2001-12-20 | 2003-07-03 | Yamanouchi Pharmaceut Co Ltd | ２−アシルアミノ−３，５−ジシアノピリジン誘導体又はその塩 |
| EP1506189A1 (en) | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| EP1388342A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| EP1545515A1 (en) | 2002-08-12 | 2005-06-29 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| JP2006512338A (ja) | 2002-12-12 | 2006-04-13 | ファルマシア・コーポレーション | マイトジェン活性化プロテインキナーゼ−活性化プロテインキナーゼ−２阻害剤としてのアミノシアノピリジンの使用法 |
| AR042667A1 (es) | 2002-12-26 | 2005-06-29 | Taisho Pharmaceutical Co Ltd | Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| CN1856307A (zh) | 2003-09-23 | 2006-11-01 | 默克公司 | 喹啉钾通道抑制剂 |
| AU2004289304A1 (en) | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Pyridine compounds |
| US20050182105A1 (en) | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
| AU2005257486A1 (en) | 2004-06-25 | 2006-01-05 | Taisho Pharmaceutical Co., Ltd. | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as CRF antagonists |
| JP2007161585A (ja) | 2004-06-25 | 2007-06-28 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
| DE102004032651A1 (de) | 2004-07-06 | 2006-02-16 | Bayer Healthcare Ag | Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen |
| EP1827438B2 (en) | 2004-09-20 | 2014-12-10 | Xenon Pharmaceuticals Inc. | Piperazin derivatives for inhibiting human stearoyl-coa-desaturase |
| CA2602514A1 (en) | 2005-03-24 | 2006-09-28 | Bayer Healthcare Ag | Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage |
| US7750015B2 (en) | 2005-05-17 | 2010-07-06 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| DE102005047558A1 (de) * | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
| WO2007124546A1 (en) | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors 3 |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
| DE102006056740A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
| DE102006056739A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
| JP2008266143A (ja) | 2007-04-16 | 2008-11-06 | Santen Pharmaceut Co Ltd | アデノシン誘導体を有効成分として含有する緑内障治療剤 |
| DE102007035367A1 (de) * | 2007-07-27 | 2009-01-29 | Bayer Healthcare Ag | Substituierte Aryloxazole und ihre Verwendung |
| DE102007036076A1 (de) * | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| DE102007036075A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Ag | Prodrugs und ihre Verwendung |
| DE102008013587A1 (de) | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
| EP2297104B1 (de) | 2008-05-29 | 2013-08-07 | Bayer Intellectual Property GmbH | 2-alkoxy-substituierte dicyanopyridine und ihre verwendung |
| DE102008062566A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Aminosäureester-Prodrugs und ihre Verwendung |
| DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
| DE102008062561A1 (de) * | 2008-12-16 | 2010-06-24 | Maxon Motor Ag | Bausatz für einen Elektromotor mit einem Drehwinkelgeber |
| DE102009006602A1 (de) * | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
| ES2554684T3 (es) | 2009-05-01 | 2015-12-22 | Inotek Pharmaceuticals Corporation | Método de reducción de la presión intraocular en humanos |
-
2011
- 2011-08-16 US US13/210,889 patent/US20120058983A1/en not_active Abandoned
- 2011-08-29 EP EP11752517.0A patent/EP2611415B1/en active Active
- 2011-08-29 EA EA201300310A patent/EA028411B1/ru not_active IP Right Cessation
- 2011-08-29 RS RS20160304A patent/RS54743B1/sr unknown
- 2011-08-29 SG SG2013014691A patent/SG187974A1/en unknown
- 2011-08-29 WO PCT/EP2011/064829 patent/WO2012028585A1/en active Application Filing
- 2011-08-29 ES ES11752517T patent/ES2570659T3/es active Active
- 2011-08-29 JP JP2013526433A patent/JP5875585B2/ja not_active Expired - Fee Related
- 2011-08-29 MA MA35698A patent/MA34489B1/fr unknown
- 2011-08-29 KR KR1020137007797A patent/KR20140091457A/ko not_active Application Discontinuation
- 2011-08-29 AU AU2011298430A patent/AU2011298430B2/en not_active Ceased
- 2011-08-29 MY MYPI2013700322A patent/MY160383A/en unknown
- 2011-08-29 PL PL11752517T patent/PL2611415T3/pl unknown
- 2011-08-29 UA UAA201303837A patent/UA111947C2/uk unknown
- 2011-08-29 HU HUE11752517A patent/HUE027295T2/en unknown
- 2011-08-29 DK DK11752517.0T patent/DK2611415T3/en active
- 2011-08-29 MX MX2013002396A patent/MX2013002396A/es active IP Right Grant
- 2011-08-29 SI SI201130809A patent/SI2611415T1/sl unknown
- 2011-08-29 CA CA2809700A patent/CA2809700A1/en not_active Abandoned
- 2011-08-29 BR BR112013005224A patent/BR112013005224A2/pt not_active IP Right Cessation
- 2011-08-29 AP AP2013006753A patent/AP3413A/xx active
- 2011-08-29 US US13/819,790 patent/US9040566B2/en not_active Expired - Fee Related
- 2011-08-29 CN CN201180052857.2A patent/CN103249400B/zh not_active Expired - Fee Related
- 2011-08-29 NZ NZ607624A patent/NZ607624A/en not_active IP Right Cessation
- 2011-09-01 TW TW100131416A patent/TWI516266B/zh not_active IP Right Cessation
-
2013
- 2013-03-01 CL CL2013000599A patent/CL2013000599A1/es unknown
- 2013-03-04 CR CR20130094A patent/CR20130094A/es unknown
- 2013-03-28 ZA ZA2013/02340A patent/ZA201302340B/en unknown
-
2014
- 2014-02-12 HK HK14101303.4A patent/HK1188138A1/xx not_active IP Right Cessation
-
2015
- 2015-05-07 US US14/705,967 patent/US20150306084A1/en not_active Abandoned
-
2016
- 2016-05-05 CY CY20161100371T patent/CY1117458T1/el unknown
- 2016-05-13 CL CL2016001164A patent/CL2016001164A1/es unknown
- 2016-05-19 HR HRP20160532TT patent/HRP20160532T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS54743B1 (sr) | Agonisti adenozina a1 za tretman glaukoma i očnog pritiska | |
| RS52474B (sr) | Spiro-ciklično jedinjenje i njegova upotreba u medicinske svrhe | |
| RS54048B1 (sr) | Paraziticidna jedinjenja dihidroizoksazola | |
| AR072373A1 (es) | Tiadiazoliloxifenilamidinas, el uso de las mismas como fungicidas en composiciones y metodos de uso, proceso para su preparacion e intermediarios de sus sintesis. | |
| NI201000107A (es) | Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa. | |
| ECSP14013245A (es) | Nuevos derivados dihidroquinolina-2-ona | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| MY161631A (en) | Herbicidal pyrimidone derivatives | |
| PH12013500745A1 (en) | Azaadamantane derivatives and methods of use | |
| UY31750A (es) | Compuestos y composiciones como inhibidores de quinasa | |
| PE20110843A1 (es) | Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica | |
| EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
| UA117151C2 (uk) | N-ациліміногетероциклічні сполуки | |
| MX2013012211A (es) | Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato. | |
| PE20090880A1 (es) | Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa | |
| AR061806A1 (es) | Derivados de alquilpiridazina como inhibidores de 11b-hsd1 (t2d) | |
| CR10671A (es) | Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas | |
| MY183326A (en) | New dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | |
| MX2019005907A (es) | Composicion para eliminacion de compuesto que contiene azufre. | |
| SV2011003902A (es) | 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5- hidroxitriptamina-6 | |
| AR097894A1 (es) | Inhibidores terapéuticos de cdk8 o uso de los mismos | |
| UY32635A (es) | Derivados de bis-(sulfonilamino) en terapia 735 | |
| MX348979B (es) | Agente de control de enfermedades de las plantas. | |
| MY148384A (en) | Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands | |
| NZ601139A (en) | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof |